TNX-102 SL
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Fibromyalgia
Conditions
Primary Fibromyalgia
Trial Timeline
Dec 1, 2013 → Aug 1, 2015
NCT ID
NCT02015234About TNX-102 SL
TNX-102 SL is a phase 3 stage product being developed by Tonix Pharmaceuticals for Primary Fibromyalgia. The current trial status is completed. This product is registered under clinical trial identifier NCT02015234. Target conditions include Primary Fibromyalgia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07464535 | Phase 1 | Completed |
| NCT04164719 | Phase 1 | Completed |
| NCT03110575 | Phase 3 | Terminated |
| NCT02421679 | Phase 2 | Completed |
| NCT02015234 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Fibromyalgia